Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAT-101 Alone or With Tislelizumab in KRAS-Mutated Advanced Solid Tumors
NCT07396090Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2026
- Primary completion
- Oct 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Open-label, single-arm trial of CAT-101 in solid tumor (advanced stage), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Adverse events at 24 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
CAT-101
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07396090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07396090.